A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
By Aino Palva (University of Helsinki), Lauri Paasonen (UPM Biomedicals),…
By Aparajita Dubey (Associate Scientific Manager at Biocon Biologics Limited)
By Unjulie Bhanot (IDBS)
By Marc Baiget-Francesch (Pharmaceutical Engineer)
By Dr Mark Behlke (Integrated DNA Technologies)